AstraZeneca sees positive late stage results for COPD

Sep 17, 2018

AstraZeneca reported that a phase 3 trial of a three-drug combination for the treatment of chronic obstructive pulmonary disease met eight out of its main objectives.

The KRONOS Phase III trial evaluated the efficacy and safety of triple combination therapy PT010 (budesonide/ glycopyrronium/formoterol fumarate) versus dual combination therapies Bevespi Aerosphere (glycopyrronium/formoterol fumarate), Symbicort Turbuhaler (budesonide/formoterol fumarate) and PT009 (budesonide/formoterol fumarate) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

The three-drug cocktail showed a significant reduction of exacerbations in patients with the disease compared with rival therapy. AstraZeneca said it plans on making a first regulatory submission for the drug in the second half of the year.

Read the press release

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments